Annual SGA
$336.36 M
-$40.86 M-10.83%
December 31, 2023
Summary
- As of February 12, 2025, SUPN annual SGA is $336.36 million, with the most recent change of -$40.86 million (-10.83%) on December 31, 2023.
- During the last 3 years, SUPN annual SGA has risen by +$135.68 million (+67.61%).
- SUPN annual SGA is now -10.83% below its all-time high of $377.22 million, reached on December 31, 2022.
Performance
SUPN SGA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly SGA
$69.75 M
-$16.15 M-18.80%
September 30, 2024
Summary
- As of February 12, 2025, SUPN quarterly SGA is $69.75 million, with the most recent change of -$16.15 million (-18.80%) on September 30, 2024.
- Over the past year, SUPN quarterly SGA has dropped by -$12.95 million (-15.66%).
- SUPN quarterly SGA is now -37.89% below its all-time high of $112.31 million, reached on September 30, 2022.
Performance
SUPN Quarterly SGA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM SGA
$2.01 B
+$59.71 M+3.06%
September 30, 2024
Summary
- As of February 12, 2025, SUPN TTM SGA is $2.01 billion, with the most recent change of +$59.71 million (+3.06%) on September 30, 2024.
- Over the past year, SUPN TTM SGA has increased by +$1.68 billion (+510.53%).
- SUPN TTM SGA is now at all-time high.
Performance
SUPN TTM SGA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Selling, General & Administrative Expenses Formula
SGA = Total Operating Expenses - Cost of Goods Sold - Research & Development
SUPN Selling, General & Administrative Expenses Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -10.8% | -15.7% | +510.5% |
| 3 y3 years | +67.6% | -15.7% | +510.5% |
| 5 y5 years | +117.4% | -15.7% | +510.5% |
SUPN Selling, General & Administrative Expenses Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -10.8% | +10.4% | -37.9% | at low | at high | +39.0% |
| 5 y | 5-year | -10.8% | +119.5% | -37.9% | +102.4% | at high | +230.2% |
| alltime | all time | -10.8% | +8284.5% | -37.9% | +5984.0% | at high | +372.4% |
Supernus Pharmaceuticals Selling, General & Administrative Expenses History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | $69.75 M(-18.8%) | $323.45 M(-3.8%) |
| Jun 2024 | - | $85.90 M(-0.7%) | $336.40 M(-0.3%) |
| Mar 2024 | - | $86.52 M(+6.4%) | $337.28 M(+0.3%) |
| Dec 2023 | $336.36 M(-10.8%) | $81.28 M(-1.7%) | $336.36 M(+2.2%) |
| Sep 2023 | - | $82.70 M(-4.7%) | $329.05 M(-8.3%) |
| Jun 2023 | - | $86.78 M(+1.4%) | $358.67 M(-3.7%) |
| Mar 2023 | - | $85.60 M(+15.7%) | $372.36 M(-1.3%) |
| Dec 2022 | $377.22 M(+23.8%) | $73.97 M(-34.1%) | $377.22 M(-6.9%) |
| Sep 2022 | - | $112.31 M(+11.8%) | $404.98 M(+11.0%) |
| Jun 2022 | - | $100.48 M(+11.1%) | $364.70 M(+9.3%) |
| Mar 2022 | - | $90.46 M(-11.1%) | $333.76 M(+9.5%) |
| Dec 2021 | $304.76 M(+51.9%) | $101.73 M(+41.2%) | $304.76 M(+17.4%) |
| Sep 2021 | - | $72.03 M(+3.6%) | $259.52 M(+7.3%) |
| Jun 2021 | - | $69.53 M(+13.1%) | $241.95 M(+9.7%) |
| Mar 2021 | - | $61.46 M(+8.8%) | $220.52 M(+9.9%) |
| Dec 2020 | $200.68 M(+31.0%) | $56.50 M(+3.7%) | $200.68 M(+12.3%) |
| Sep 2020 | - | $54.46 M(+13.2%) | $178.64 M(+9.2%) |
| Jun 2020 | - | $48.10 M(+15.6%) | $163.52 M(+5.4%) |
| Mar 2020 | - | $41.61 M(+20.7%) | $155.20 M(+0.4%) |
| Dec 2019 | $153.25 M(-0.9%) | $34.46 M(-12.4%) | $154.55 M(-1.5%) |
| Sep 2019 | - | $39.34 M(-1.1%) | $156.95 M(-1.0%) |
| Jun 2019 | - | $39.78 M(-2.9%) | $158.50 M(-0.2%) |
| Mar 2019 | - | $40.97 M(+11.1%) | $158.82 M(+2.7%) |
| Dec 2018 | $154.70 M(+12.2%) | $36.86 M(-9.9%) | $154.70 M(+2.0%) |
| Sep 2018 | - | $40.89 M(+2.0%) | $151.60 M(+0.0%) |
| Jun 2018 | - | $40.10 M(+8.8%) | $151.53 M(+3.4%) |
| Mar 2018 | - | $36.85 M(+9.1%) | $146.52 M(+6.2%) |
| Dec 2017 | $137.91 M | $33.76 M(-17.3%) | $137.91 M(+3.5%) |
| Sep 2017 | - | $40.83 M(+16.4%) | $133.19 M(+12.8%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2017 | - | $35.08 M(+24.2%) | $118.05 M(+8.2%) |
| Mar 2017 | - | $28.24 M(-2.8%) | $109.09 M(+2.9%) |
| Dec 2016 | $106.01 M(+19.0%) | $29.05 M(+13.2%) | $106.01 M(+5.5%) |
| Sep 2016 | - | $25.68 M(-1.7%) | $100.52 M(+2.8%) |
| Jun 2016 | - | $26.12 M(+3.8%) | $97.75 M(+3.1%) |
| Mar 2016 | - | $25.16 M(+6.8%) | $94.82 M(+6.5%) |
| Dec 2015 | $89.06 M(+22.7%) | $23.57 M(+2.9%) | $89.06 M(+6.6%) |
| Sep 2015 | - | $22.90 M(-1.3%) | $83.56 M(+7.0%) |
| Jun 2015 | - | $23.19 M(+19.5%) | $78.10 M(+4.9%) |
| Mar 2015 | - | $19.40 M(+7.4%) | $74.49 M(+2.6%) |
| Dec 2014 | $72.61 M(+30.6%) | $18.06 M(+3.5%) | $72.61 M(+4.1%) |
| Sep 2014 | - | $17.45 M(-10.9%) | $69.78 M(+4.2%) |
| Jun 2014 | - | $19.58 M(+11.7%) | $66.95 M(+12.4%) |
| Mar 2014 | - | $17.53 M(+15.1%) | $59.59 M(+7.2%) |
| Dec 2013 | $55.59 M(+176.1%) | $15.22 M(+4.1%) | $55.59 M(+13.3%) |
| Sep 2013 | - | $14.62 M(+19.7%) | $49.05 M(+27.4%) |
| Jun 2013 | - | $12.21 M(-9.7%) | $38.50 M(+24.5%) |
| Mar 2013 | - | $13.53 M(+55.9%) | $30.93 M(+53.7%) |
| Dec 2012 | $20.13 M(+153.9%) | $8.68 M(+113.1%) | $20.13 M(+41.4%) |
| Sep 2012 | - | $4.08 M(-12.3%) | $14.23 M(+22.1%) |
| Jun 2012 | - | $4.64 M(+70.3%) | $11.66 M(+30.9%) |
| Mar 2012 | - | $2.73 M(-2.0%) | $8.91 M(+12.4%) |
| Dec 2011 | $7.93 M(+56.1%) | $2.79 M(+85.5%) | $7.93 M(+16.0%) |
| Sep 2011 | - | $1.50 M(-20.8%) | $6.83 M(+28.1%) |
| Jun 2011 | - | $1.90 M(+8.5%) | $5.33 M(+55.1%) |
| Mar 2011 | - | $1.75 M(+3.3%) | $3.44 M(+103.3%) |
| Dec 2010 | $5.08 M(+9.3%) | $1.69 M(+47.6%) | $1.69 M(+47.6%) |
| Dec 2009 | $4.65 M(+8.4%) | $1.15 M | $1.15 M |
| Dec 2008 | $4.29 M(+6.9%) | - | - |
| Dec 2007 | $4.01 M | - | - |
FAQ
- What is Supernus Pharmaceuticals annual SGA?
- What is the all time high annual SGA for Supernus Pharmaceuticals?
- What is Supernus Pharmaceuticals annual SGA year-on-year change?
- What is Supernus Pharmaceuticals quarterly SGA?
- What is the all time high quarterly SGA for Supernus Pharmaceuticals?
- What is Supernus Pharmaceuticals quarterly SGA year-on-year change?
- What is Supernus Pharmaceuticals TTM SGA?
- What is the all time high TTM SGA for Supernus Pharmaceuticals?
- What is Supernus Pharmaceuticals TTM SGA year-on-year change?
What is Supernus Pharmaceuticals annual SGA?
The current annual SGA of SUPN is $336.36 M
What is the all time high annual SGA for Supernus Pharmaceuticals?
Supernus Pharmaceuticals all-time high annual SGA is $377.22 M
What is Supernus Pharmaceuticals annual SGA year-on-year change?
Over the past year, SUPN annual SGA has changed by -$40.86 M (-10.83%)
What is Supernus Pharmaceuticals quarterly SGA?
The current quarterly SGA of SUPN is $69.75 M
What is the all time high quarterly SGA for Supernus Pharmaceuticals?
Supernus Pharmaceuticals all-time high quarterly SGA is $112.31 M
What is Supernus Pharmaceuticals quarterly SGA year-on-year change?
Over the past year, SUPN quarterly SGA has changed by -$12.95 M (-15.66%)
What is Supernus Pharmaceuticals TTM SGA?
The current TTM SGA of SUPN is $2.01 B
What is the all time high TTM SGA for Supernus Pharmaceuticals?
Supernus Pharmaceuticals all-time high TTM SGA is $2.01 B
What is Supernus Pharmaceuticals TTM SGA year-on-year change?
Over the past year, SUPN TTM SGA has changed by +$1.68 B (+510.53%)